Oregovomab
Oregovomab (marketed under the trade name OvaRex) is a mouse monoclonal antibody it binds to the antigen CA125, a carbohydrate antigen. It is designed for the treatment of ovarian cancer.[1]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Mouse |
Target | CA125 |
Clinical data | |
Trade names | OvaRex |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Molar mass | ca. 150 kg/mol |
![]() ![]() |
This drug was developed by AltaRex Corp.
Adverse drug effects
gollark: The power of automated bees.
gollark: What if we create a RocketRace neural network so it can automatically generate motivation?
gollark: > and at hating against capitalism<:bees:724389994663247974> you.
gollark: https://0ver.org/
gollark: ++remind 3d <@!156021301654454272> is to be considered <@!156021301654454272>
References
- Statement On A Nonproprietary Name Adopted By The USAN Council - Oregovomab, American Medical Association.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.